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Abstract
The last 10-12 years have seen an avalanche of changes in both the management of incontinence and
genital prolapse. So many new procedures continue to appear that often the clinician is confused as to
which approach to adopt. Complications are now being reported, creating a need to reappraise the
situation.
Introduction and context
Previously, anterior vaginal repair and colposuspension
were the main available procedures to combat incon-
tinence, however, the former was largely discredited for
having a low 5-year dry rate [1] (although dry rate is
d i f f i c u l tt od e f i n ea n dm a yv a r ya c c o r d i n gt ot h e
perspective of the clinician or the patient). A number of
needle suspension procedures (for example, Stamey or
Raz) were popular for a while but also had poor dry rates.
Suburethral autologous slings are not new; the use of the
gracilis muscle was described in 1907. Since then,
modifications have used other muscles such as pyrami-
dalis, rectus fascia, and fascia lata. Traditionally, this was
considered an operation for patients who remained
incontinent despite previous bladder neck surgery. If the
operation is performed as a primary procedure, a 90%
success rate is quoted, but like colposuspension, the
procedure carries significant complications, with a de novo
detrusor instability rate of around 16% and a post-
operative voiding disorder rate of 10%.
Currently, there is a wide range of approaches for
restoring continence, ranging from injectables (bulking
agents) to midurethral slings. These may be retropubic
midurethral slings, for example, tension-free vaginal tape
(TVT) or transobturator midurethral sling (TOT) proce-
dures. The latter may be introduced by an outside-in or
an inside-out technique, and there are numerous
varieties of tape to apply, with differing pore size and
tensile strength confounding the comparison of data
between clinical series.
Pelvic organ prolapse (POP) has classically been treated
with standard surgical approaches, using midline plica-
tion for anterior and posterior compartmental defects
and either abdominal or laparoscopic sacrocolpopexy or
sacrospinus fixation for apical prolapse. Magnetic
resonance imaging [2,3] has contributed to the under-
standing of anatomical defects so that lateral defects
along the line of the arcus tendinious can now be
detected, altering the approach to repairs in some cases.
Synthetic meshes and biological grafts have been
introduced along with numerous materials and imple-
mentation procedures, but their use has not been backed
up by robust randomised controlled trial (RCT) data.
Research into the use of synthetic meshes often takes the
form of small observational or retrospective studies or
case series, often with a short follow-up and numerous
confounding variables.
Long-term data are essential for any technique as initial
promising results may be misleading. A classical example
of this is NASHA-Dx (non-animal stabilised hyaluronic
acid/dextranomer), or Zuidex
TM, used to treat stress
incontinence. The initial multicentre study [4] demon-
strated a 77% response rate at 12 months. However,
reported cases of pseudocysts have appeared [5] and
stress urinary incontinence (SUI) may return when the
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described [6]. Zuidex
TM has now been withdrawn from
the UK market.
Recent advances
Stress urinary incontinence
Cross-linked polydimethylsiloxane (Macroplastique®)
has been available since 1991 to treat urinary incon-
tinence and is the European bulking agent leader. The first
North American single-blinded multicentrestudy ofcross-
linked polydimethylsiloxane has just been published [7]
with an intention-to-treat analysis. A total of 247 women
with intrinsic sphincter deficiency were randomly
assigned to receive Macroplastique® or Contigen®, which
served as a control. Repeat injection was allowed at
3-month follow-up. Effectiveness was determined at 12
months using assessment of leakage by Stamey grade,
1-hour pad test, and urinary incontinence quality-of-life
(QoL) scale scores. Many of these women had been
incontinent for a long time (average of 11.2 years), and
24% had undergone prior incontinence surgery. At 12
months, 61.5% of the Macroplastique® patients and 48%
of the Contigen® controls had improved by 1 Stamey
grade. The total dry rates were 36.9% for Macroplastique®
patients and 24.8% for controls (P < 0.05). QoL score
changesin the two groupsweresimilar.A 2-yearextension
study is ongoing. This study, providing larger numbers,
supports the favourable small-cohort 5-year follow-up
data on Macroplastique® [8,9], which also demonstrated
minimal complications.
Midurethral slingproceduresarenowcommonplace,with
10- to 11-year follow-up data available for TVTs. Data
from the Austrian Registry are now available for the TOT
procedure as well [10] and contain data on 2,543
operations with 11 different tape systems. Intra-operative
complicationsoccurredin4.7%ofcases, includingbleeding
and 2 urethral, 10 bladder, and 10 vaginal perforations.
Re-operations (including 24 tapes cut or loosened) were
needed for 57 women, of whom 11 had vaginal erosions.
There was one retropubic haematoma. Bladder perfora-
tion occurred more often with outside-in than inside-out
techniques. Data on incontinence surgery extracted from
the Danish National Patient Register revealed an incom-
plete registration of complications and re-operations,
especially in the TVT group [11], and highlighted the need
for data that are more transparent and robust.
So-called ‘needleless’ tapes and ‘minislings’ are now
being introduced for SUI. These are smaller than
conventional tapes and can be inserted in the outpatient
setting under local anaesthesia. Data are limited but a
randomised trial comparing TVT with the MiniArc
TM
(American Medical Systems) showed significantly less
satisfactory results in the latter group, both objectively
and subjectively, at 6 months [12]. It has been postulated
that this tape is too short to obtain adequate fixation. A
randomised trial of a TVT-obturator (TVT-O®; Gynecare)
versus the Contasure Needleless® (Neomedic Interna-
tional) single incision tape, however, showed equivalent
objective and subjective results at 1 year [13], with
significantly more leg pain in the TVT-O® group. The
NICE (National Institute for Health and Clinical
Excellence) Interventional Procedure Guidance [14]
quotes current evidence as inadequate and suggests
that insertion of these devices should be confined to
research studies or allowed only if data areentered onto a
national register.
Combining continence procedures and prolapse surgery
Several groups have tried to rationalise the long-standing
questions of whether to perform prophylactic continence
procedures during POP corrective surgery and whether to
embarkonPOP surgery wheninserting midurethraltapes.
The Netherlands TVT database showed good 2-year
success rates when TVT was performed with concomitant
prolapse surgery [15]. Fifty-nine women undergoing TVT
and POP surgery were compared with 687 women having
TVT alone. The IIQ-7 (Incontinence Impact Question-
naire) and the UDI-6 (Urogenital Distress Inventory) were
used toevaluate outcomes. Inthis study,all of the women
required continence procedures but only a few had
coexisting prolapse. It is reassuring to know that the
tape was equally successful whether inserted alone or in
conjunction with a prolapse repair. The more vexing
clinical question is whether prophylactic tapes should be
inserted in patients who are undergoing prolapse surgery
but who do not currently leak, to prevent occult
incontinence from being unmasked. In this situation, a
number of women will receive unnecessary surgery and
may develop complications associated with tape inser-
tion. The prediction of those who will develop post-
operative incontinence is also problematic.
One study followed 1,356 women for 18 months (that
is, 6 months pre-operatively to 1 year post-operatively)
and found that 34.4% had undergone concomitant POP
surgery (usually anterior repair) at the time of the tape
insertion. The women who had received prolapse repairs
were significantly less likely to develop a new prolapse or
undergo repeat surgery for prolapse or surgery for SUI
than those who had received tape alone. The latter group,
however, had less bladder neck outlet obstruction and
developed less urethral diverticulae [16].
Clinical algorithms are needed to guide the clinician on
this matter; there have been four International Consulta-
tions on Incontinence (ICIs) that have developed
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bladders. The recommendation is that, if stress incon-
tinence surgery is required, coexisting prolapse should be
corrected. In the fourth ICI, it was stated that no grade A
recommendations could be given due to lack of
evidence, and the optimal diagnostic algorithm and
need for concomitant SUI surgery have yet to be
determined [17]. One study attempted to provide this
in relation to the insertion of midurethral tape at the
time of POP repair [18]. Tapes were inserted only if there
was urodynamically proven or occult SUI. In cases of
clinical or no incontinence, no tape was inserted. In the
group with tape insertion, there was an 8.5% risk of tape
excision, cutting the tape, or urethrolysis. In the group
with POP repair and no tape, there was an 8.3% risk of
requiring a bladder neck procedure later; that is, the risk
of obstructive difficulties post-sling was equal to the risk
of persistent SUI post-operatively with no sling. Those
patients with clinical incontinence, in whom tapes were
withheld, were found to have a 30% chance of requiring
a continence procedure post-POP repair. This group was
added to the algorithms to receive a midurethral tape at
the time of the original surgery. The severity of SUI is an
important parameter that influences results after TVT-O
and TVT and could be used by surgeons in selecting the
most effective intervention [19].
Pelvic organ prolapse
Surgery for POP is governed by a need to maintain pain-
free function and a desire to prevent recurrence (risk
quoted at 15-25%). Clinicians are divided on whether
biografts are preferable to synthetic mesh, which can
incur complications such as erosion and ridging, and
whether additional support should be inserted only in
re-do surgery or as first-line treatment.
A meta-analysis of 10 RCTs (n = 1,087 patients) using
adjuvant materials versus standard surgery for anterior
vaginal prolapse showed a lower objective recurrence
rate at 1 year in those cases in which biological adjuvant
material (odds ratio [OR] 0.56, 95% confidence interval
[CI] 0.34-0.92) and absorbable synthetic adjuvant
material (OR 0.44, 95% CI 0.21-0.89) were used [20].
A recentprospectivestudyrandomlyassigned 190 women
with recurrent symptomatic stage 2 (or greater) cystocele
to receive either Gynemesh® (Ethicon, Inc.), a knitted,
monofilament, large-pore polypropylene, non-absorb-
able mesh, or Pelvicol® (CR Bard, Inc.), a porcine dermis
acellular graft [21]. All patients received full objective
assessment, including POP-Q (POP-quantification) sta-
ging, urodynamics, P-QoL (Prolapse Quality of Life
Questionnaire) and short form of PISQ-12 (Pelvic
Organ Prolapse – Urinary Incontinence Sexual
Questionnaire). Ninety-six women, of whom 60 had
previously undergone hysterectomy, were randomly
assigned to Gynemesh®, and 94, including 54 hysterecto-
mised women, received Pelvicol®. All patients completed
a 2-year follow-up. Anterior vaginal wall recurrence was
observed in 28.1% of the Gynemesh® group and 43.6%
of the Pelvicol® group. This did not reach statistical
significance (P = 0.06). None of the women with
recurrence was symptomatic enough to require re-opera-
tion. Mesh erosions were encountered in six of the
Gynemesh® group (6.3%) and in none of the Pelvicol®
group (P = 0.02). All erosions were obvious by 6 months
after surgery. Patients in the Pelvicol® group exhibited
improvement in all but one of the QoL domains as
compared with improvement in four domains with
Gynemesh®. Sexuality was unchanged on PISQ-12 scores
in the Gynemesh® but showed a significant improvement
inthe Pelvicol®group (P = 0.03).Theauthorscommented
that meticulous attention to haemostasis and avoidance
of extensive dissection were required and might be the
reason for the lack of erosions in the Pelvicol® group
compared with results from other papers [22,23]. The
high prevalence of hysterectomised women in the
Gynemesh® erosion group is concordant with other
papers [24] that suggested that prior hysterectomy may
be a factor contributing to this complication.
A prospective longitudinal study now offers 5-year
follow-up data on anterior and posterior vaginal wall
prolapse with Pelvicol® [25]. In all, 72 patients with 82
defects had objective cure rates of 81.6% for anterior
defects and 86.4% for posterior defects. The failure rate
was six times higher for concomitant anterior and
posterior repairs. Complete replacement of the endo-
pelvic fascia has a better outcome than using classical
plication or plication augmentation repairs.
A number of studies have now reported on complica-
tions associated with mesh. A retrospective cohort study
involving 329 women from two district general hospitals
and two tertiary urogynaecology referral units reviewed
the short-term outcomes and complications after various
prolapse repair mesh devices (76% Gynecare and 24%
American Medical Systems devices). Operative compli-
cations included bladder injury (1.6%) and rectal injury
(1.1%), and two women had serious vascular injuries.
Post-operative complications included buttock pain
(5.2%), vaginal erosion (10%), one bladder erosion,
and two serious infections (0.7%), leading to necrotising
fasciitis in one case [26]. Five percent of the women had
persistent prolapse at 3 months. Concerns have been
echoed in the MAUDE (Manufacturer and User Facility
Device Experience Database) of the US Food and Drug
Administration (FDA) [27].
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French centres raised similar concerns [28]. Even with a
short follow-up of 6 months, there was a 33.6% ‘late
complications’ rate, including granulomas or prosthetic
expositions (11.3%), relapse of prolapse (6.9%), and
5.4% de novo SUI. Early post-surgical complications
included abscesses (0.29%), haematomas (1.9%), two
vesico-vaginal fistulae, and one recto-vaginal fistula.
Multivariate analysis confirmed that prior hysterectomy
or placing an isolated anterior prosthesis were risk factors.
The FDA has now issued a warning regarding complica-
tions associated with mesh, citing reports from nine
different manufacturers, involving over 1,000 people with
severe complications [29]. A carefully conducted case
series demonstrated mesh complications in 1 in 20
women [30], with little evidence to support advantage.
Sexual dysfunction is an area now being considered in
greater depth. Ridging and contraction of mesh pros-
theses remain potential causes of dyspareunia in younger
patients. In a retrospective analysis, 87 women under-
going infracoccygeal sacropexy for apical vaginal pro-
lapse were followed up for a mean of 27 months [31].
Post-operative perineal pain occured in 10%, dyschesia
(difficulty or pain in defecating) in 5%, and dyspareunia
in 6% of cases. Contraction may be related to inadequate
tissue in-growth into the mesh [32]. More recently,
animal models have shown less contraction with
atelcollagen-coated mesh [33].
Implications for clinical practice
The management of pelvic floor dysfunction is a rapidly
changing field. The challenge is to provide minimal
access techniques that reduce recurrence rates but with-
out an increase in morbidity. Data that are more robust are
required on the newer interventions with additional
randomised trials, longer duration of follow-up, and
clearer definitions of outcomes, using standardised
assessment tools. Bowel, bladder, and sexual parameters
need to be assessed as women are demanding quality of
life following SUI and POP surgery and frequently
remain sexually active for longer with modern hormonal
interventions. Various risk factors that could lead to
clinical algorithms to help the clinician to determine
which procedure is right for the patient have now been
identified. Surgical techniques need to be reviewed and
taught by experienced practitioners aiming at adequate
throughput. Personal practice should be audited.
National and international databases are needed for
pooled morbidity and outcome measures.
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